Search

Takeda Pharmaceutical Co Ltd ADR

Nyitva

SzektorEgészségügy

18.46 -1.23

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

18.37

Maximum

18.53

Fő mutatók

By Trading Economics

Bevétel

138B

113B

Értékesítés

105B

1.2T

P/E

Szektor átlag

42.622

56.659

Egy részvényre jutó nyereség

0.48

Osztalékhozam

3.42

Profit margin

9.279

Munkavállalók

47,029

EBITDA

180B

337B

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+133.08% upside

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

3.42%

2.18%

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

1.7B

57B

Előző nyitás

19.69

Előző zárás

18.46

Hangulat hírek alapján

By Acuity

100%

0%

327 / 339 Rangsor szerint Healthcare

Takeda Pharmaceutical Co Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 3. 23:56 UTC

News

Missouri American Water acquired Neosho's water systems for $34.5 million, adding 5,400 customers. Shares of American Water Works traded higher in after-market hours.

2026. szept. 3. 23:56 UTC

News
Correlated Moves

Paychex receives a buy rating on strong revenue growth and strategic AI integration. After-market trading has shown little change since Thursday's close.

2026. szept. 3. 23:56 UTC

News

Jefferies initiated coverage on Nexgen Energy with a Buy rating and a C$21 price target. Shares moved higher in after-market hours.

2026. szept. 3. 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit over misleading statements about its Phase III Fianlimab-Libtayo Study, with shares trading lower in after-market hours.

2026. szept. 3. 23:51 UTC

News
Social Media

Dutch Bros Inc filed a mixed securities shelf registration, enabling potential issuance of various securities. Shares are trading higher in after-market hours.

2026. szept. 3. 23:51 UTC

News
Social Media

Tesla Inc. shares are lower in after-market trading following the invite-only launch event for its Cybercab in Austin, as details remain restricted.

2026. szept. 3. 23:46 UTC

News

Weyerhaeuser Co remains about 4.95% below its 20-day moving average. Shares were roughly flat in after-market hours following a price target cut to $28.

2026. szept. 3. 23:46 UTC

News
Social Media

Hewlett Packard Enterprise shares are lower in after-market trading, despite strong networking revenue guidance and broader market gains ahead of employment data.

2026. szept. 3. 23:41 UTC

News

JP Morgan upgrades CPRT to Overweight, raises target to $40 after-market.

2026. szept. 3. 23:41 UTC

News

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

2026. szept. 3. 23:36 UTC

News

Ulta Beauty will participate in a Fireside Chat at the Barclays Global Consumer Conference on September 10, 2026. Shares are higher in after-market trading.

2026. szept. 3. 23:31 UTC

News

Honeywell International Inc shares are lower in after-hours trading, despite broader market gains. The stock is near the lower end of its one-month range.

2026. szept. 3. 23:26 UTC

News

Jefferies maintained a Buy rating on Five Below and raised its price target to $420. Shares are trading higher in after-market hours following the updates.

2026. szept. 3. 23:21 UTC

News
Social Media

Meta Platforms Inc. shares are higher in after-market hours, supported by a Buy rating from Bank of America with a price target of $810.

2026. szept. 3. 23:21 UTC

News

Thermo Fisher Scientific shares are lower in after-market hours despite CLSA initiating coverage with an Outperform rating and a $748 price target.

2026. szept. 3. 23:11 UTC

News

Ethereum is trading higher during Thursday's session, remaining above its 20-day moving average and near the upper end of its one-month range.

2026. szept. 3. 23:11 UTC

News

Ethereum is trading higher today, remaining above its 20-day moving average and near the upper end of its one-month trading range.

2026. szept. 3. 23:05 UTC

News

USD/HKD trades roughly flat amid stable market activity. An increase in USDE supply to $4.26 billion may influence dynamics but has not impacted prices today.

2026. szept. 3. 23:05 UTC

News

WEX Inc. shares decline in after-market hours despite announcing an integration with Driivz Ltd. for electric vehicle charging solutions, with a fair value of $187.30.

2026. szept. 3. 23:05 UTC

Correlated Moves
News

Elastic NV plans to integrate OpenAI GPT cyber models into its Elastic Security platform, enhancing security capabilities. Shares are trading roughly flat in after-market hours.

2026. szept. 3. 23:05 UTC

Macro Event
Correlated Moves
News

The USD/PLN exchange rate is declining amid mixed U.S. jobless claims data, with initial claims rising slightly above expectations.

2026. szept. 3. 23:02 UTC

News
Social Media

Lululemon Athletica reported second-quarter revenue of $2.42 billion, below estimates. The stock fell sharply in after-market hours, reaching its lowest level since May 2018.

2026. szept. 3. 23:02 UTC

News
Correlated Moves
Social Media

DocuSign shares rise in after-market trading following strong fiscal Q2 results and raised revenue guidance, despite earlier pulling back from a session high.

2026. szept. 3. 23:01 UTC

News

PulteGroup Inc shares are higher in after-market hours following a Buy rating from StoneX analyst Michael, who set a price target of $148.00.

2026. szept. 3. 23:01 UTC

News

eGain Corp shares are lower in after-market trading following disappointing fiscal 2027 guidance, despite reporting revenue and adjusted EPS that exceeded estimates.

2026. szept. 3. 23:01 UTC

News

Concrete Pumping Holdings reported strong Q3 results, raising revenue guidance and announcing a quarterly dividend, driving shares higher in after-market trading.

2026. szept. 3. 23:01 UTC

News
Social Media
Event

UiPath Inc shares declined in after-market hours despite reporting second-quarter revenue of $410 million and raising its fiscal year 2027 outlook.

2026. szept. 3. 23:01 UTC

News
Event

Oxford Industries reports second-quarter sales of $394 million and lowers full-year adjusted EPS guidance to $1.60-$2.00, leading shares lower in after-market hours.

2026. szept. 3. 23:01 UTC

News
Social Media

Strategy Inc shares declined after hours, retracing from earlier gains amid social media discussions and news from Iran affecting sentiment.

2026. szept. 3. 23:01 UTC

News
Event
Social Media

Smith & Wesson Brands reported strong Q1 results, with net sales of $112.6 million and adjusted EPS of $0.06, boosting shares in after-market trading.

Társak összehasonlítása

Árváltozás

Takeda Pharmaceutical Co Ltd ADR Előrejelzés

Célár

By TipRanks

133.08% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 43.61 USD  133.08%

Magas 43.608 USD

Alacsony 43.608 USD

1 Wall Street elemző 12 hónapos célárain alapulva a(z)Takeda Pharmaceutical Co Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

1 ratings

1

Vétel

0

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
help-icon Live chat